Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
University of South Alabama has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, so the portfolio is distributed across separate examination assignments.
CHO, DAVID H is the busiest examiner, with 1 pending matter. Because no examiner handles more than that figure, prosecution planning should be organized by individual application rather than around a dominant examiner relationship.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18224879 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | MOSHER, ERIC PARKER | — |
| 17273940 | INFECTION-INDUCED ENDOTHELIAL AMYLOID COMPOSITIONS AS ANTIMICROBIALS | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730598 | Dihydronicotinamide Riboside (NRH) Therapy for Osteoarthritis and other Conditions | CHO, DAVID H | — |
| 17273940 | INFECTION-INDUCED ENDOTHELIAL AMYLOID COMPOSITIONS AS ANTIMICROBIALS | BALLARD, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1612 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730598 | Dihydronicotinamide Riboside (NRH) Therapy for Osteoarthritis and other Conditions | CHO, DAVID H | 1693 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18224879 | POLY(2-OXAZOLINE)N-f-MLF DERIVATIVE CONJUGATES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE | MOSHER, ERIC PARKER | 1612 | §103§112Other | Final Rejection | — | Pending | Jul 21, 2023 |
| 17273940 | INFECTION-INDUCED ENDOTHELIAL AMYLOID COMPOSITIONS AS ANTIMICROBIALS | BALLARD, KIMBERLY | 1675 | §102§112 | Non-Final OA | — | Pending | Mar 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of South Alabama has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
David H Cho has the most, with 1 of University of South Alabama's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
